GlassScriptPhysician profile
Adil A Mohammed
NPI 1881929693
$3,406.87
in general payments reported to CMS, 2019-2025
22 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $316 · 2021: $462 · 2022: $528 · 2023: $1,015 · 2024: $472 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $613.56 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $388.57 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $373.29 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $301.23 | 2022-2025 | Caplyta |
| Abbvie INC. | $253.71 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $204.72 | 2019-2022 | |
| Axsome Therapeutics, INC. | $200.30 | 2023-2025 | Auvelity |
| Allergan, INC. | $161.23 | 2019-2021 | |
| Alkermes, INC. | $147.91 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $144.97 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $137.29 | 2020-2024 | Trintellix |
| Lundbeck LLC | $89.91 | 2020-2025 | Rexulti |
| Tris Pharma INC | $78.78 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $72.65 | 2023-2025 | Azstarys |
| Eisai INC. | $53.22 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $36.15 | 2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $35.89 | 2023-2024 | Qelbree, Qelbree |
| Bausch Health US, LLC | $34.55 | 2024-2025 | Aplenzin, Wellbutrin |
| Bioxcel Therapeutics, INC. | $24.18 | 2024 | Igalmi |
| Neos Therapeutics, LP | $20.67 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.31 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adil Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.